- Home
- GOSS vs ATYR Comparison
GOSS vs ATYR Comparison
Compare GOSS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ATYR
- Stock Information
- Founded
- GOSS 2015
- ATYR 2005
- Country
- GOSS United States
- ATYR United States
- Employees
- GOSS N/A
- ATYR N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOSS Health Care
- ATYR Health Care
- Exchange
- GOSS Nasdaq
- ATYR Nasdaq
- Market Cap
- GOSS 262.5M
- ATYR 306.2M
- IPO Year
- GOSS 2019
- ATYR 2015
- Fundamental
- Price
- GOSS $1.40
- ATYR $5.22
- Analyst Decision
- GOSS Strong Buy
- ATYR Strong Buy
- Analyst Count
- GOSS 4
- ATYR 6
- Target Price
- GOSS $7.75
- ATYR $20.20
- AVG Volume (30 Days)
- GOSS 1.3M
- ATYR 2.5M
- Earning Date
- GOSS 08-11-2025
- ATYR 08-12-2025
- Dividend Yield
- GOSS N/A
- ATYR N/A
- EPS Growth
- GOSS N/A
- ATYR N/A
- EPS
- GOSS N/A
- ATYR N/A
- Revenue
- GOSS $124,590,000.00
- ATYR N/A
- Revenue This Year
- GOSS N/A
- ATYR $960.85
- Revenue Next Year
- GOSS $91.14
- ATYR $1,283.47
- P/E Ratio
- GOSS N/A
- ATYR N/A
- Revenue Growth
- GOSS N/A
- ATYR N/A
- 52 Week Low
- GOSS $0.55
- ATYR $1.42
- 52 Week High
- GOSS $1.55
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- GOSS 57.95
- ATYR 62.87
- Support Level
- GOSS $1.22
- ATYR $5.02
- Resistance Level
- GOSS $1.36
- ATYR $5.98
- Average True Range (ATR)
- GOSS 0.08
- ATYR 0.45
- MACD
- GOSS -0.00
- ATYR -0.04
- Stochastic Oscillator
- GOSS 66.07
- ATYR 52.94
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.